/images/ppid_59c68470-image-176287754739337143.webp)
What is the story about?
Biocon Ltd
posted a nearly 20% year-on-year rise in consolidated revenue to ₹4,296 crore for the quarter ended September 2025 (Q2 FY26), fuelled by strong growth in its biosimilars business and continued international expansion.
According to the company’s filing, operating profit (EBITDA) rose over 40% YoY, supported by higher product volumes and cost efficiencies. The biosimilars segment — Biocon’s largest growth engine — benefited from expanded market access in the US and Europe as well as steady gains in emerging markets.
Chairperson Kiran Mazumdar-Shaw said the results reflected the “resilience of Biocon’s diversified business model” and reaffirmed the company’s focus on innovation-led, affordable healthcare. She added that R&D investments and pipeline progress would remain priorities as Biocon deepens its presence in global biologics.
The generics and research-services businesses continued to show moderate growth, with management highlighting ongoing efforts to strengthen manufacturing capabilities and regulatory compliance.
Investors now await Biocon’s post-results commentary for updates on its upcoming launches and guidance for the second half of FY26.
According to the company’s filing, operating profit (EBITDA) rose over 40% YoY, supported by higher product volumes and cost efficiencies. The biosimilars segment — Biocon’s largest growth engine — benefited from expanded market access in the US and Europe as well as steady gains in emerging markets.
Chairperson Kiran Mazumdar-Shaw said the results reflected the “resilience of Biocon’s diversified business model” and reaffirmed the company’s focus on innovation-led, affordable healthcare. She added that R&D investments and pipeline progress would remain priorities as Biocon deepens its presence in global biologics.
The generics and research-services businesses continued to show moderate growth, with management highlighting ongoing efforts to strengthen manufacturing capabilities and regulatory compliance.
Investors now await Biocon’s post-results commentary for updates on its upcoming launches and guidance for the second half of FY26.
/images/ppid_59c68470-image-177090765525651885.webp)
/images/ppid_59c68470-image-177090761262642052.webp)
/images/ppid_59c68470-image-177090769508011063.webp)
